Clinical trial
An Open-label Clinical Study to Explore the Safety, Tolerability and Preliminary Efficacy of REGEND001 for Treatment of Idiopathic Pulmonary Fibrosis (IPF).
NCT05657184 is registered in ClinicalTrials.gov with Regend Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Clinical Study to Explore the Safety, Tolerability and Preliminary Efficacy of REGEND001 for Treatment of Idiopathic Pulmonary Fibrosis (IPF).
- Lead sponsor
- Regend Therapeutics
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 19, 2021
- Completion date
- June 9, 2023
- Enrollment
- 12 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.